Restoring Immune Balance by Clearing Pathogenic DNA
Validated non-immunosuppressive Systemic Lupus Erythematosus treatment built for translational efficiency.
The Problem
Lupus Is Driven by Pathogenic DNA Accumulation
Systemic lupus erythematosus (SLE) is characterized by loss of immune tolerance to self-DNA, leading to chronic inflammation and organ damage particularly in lupus nephritis.
In healthy individuals, circulating DNA is rapidly cleared. In SLE patients, this clearance fails.
The Solution
We have developed an engineered DNASE1L3 to restore DNA clearance while minimizing immunogenicity and extending serum half-life
Our Team
Ardiyon Bio was founded out of the Texas Tech University Innovation System and is working from lab space at the One Health Incubator in Lubbock, Texas
Jon McCord, PhD
Developed technology underlying Ardiyon Bio during postdoctoral Research
Experienced regulatory FDA policy specialist
Bryan Sutton, PhD
Professor at Texas Tech University Health Sciences Center
Entrepreneurial background and co-founded Bedrock Therapeutics
Peter Keyel, PhD
Professor at Texas Tech University
Over a decade of immunology experience with Lupus pathology and treatment development